Cost-Effectiveness of ACTH vs. ACT Chemotherapy Regimens at RSUP Dr. M. Djamil
Main Article Content
Abstract
Introduction: Breast cancer is one of the most common cancers and is often diagnosed at a late stage, especially in Indonesia. This highlights the need for cost-effective treatment options. ACT (Adriamycin, Cyclophosphamide, and Taxane) and ACTH (ACT plus Herceptin/Trastuzumab) are used chemotherapy regimens, but studies comparing their cost-effectiveness are still limited. This study aimed to evaluate the cost-effectiveness of ACT versus ACTH for breast cancer treatment using tumor volume reduction. Method: A retrospective cost-effectiveness study was carried out at Dr. M. Djamil Hospital by comparing direct medical costs and tumor volume changes in breast cancer patients treated with ACT or ACTH regimens. Effectiveness was based on the average change in tumor volume, and cost-effectiveness was evaluated using the Incremental Cost-Effectiveness Ratio (ICER). Results: The mean tumor volume reduction in the ACT group was 2820.85 ± 11190.42 cm³, and significantly higher at 9273.50 ± 60101.33 cm³ in ACTH, although the difference was not statistically significant (p = 0.614). The average direct medical cost for ACTH was IDR 67,138,579, compared to IDR 13,005,027 for ACT. The ICER calculation resulted in IDR-838,935 per cm³ of tumor reduction, while the negative ICER might suggest cost savings, it does not imply that ACTH is a dominant strategy indicating that ACTH incurred a higher cost with less effectiveness per unit of tumor reduction than ACT. Conclusion: The high associated cost leads to a negative ICER, suggesting that ACT may be more cost-effective in this setting. These findings are critical for optimizing chemotherapy choices within limited healthcare budgets.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.
References
[1]. Handayani F, Fitria N, Sari YO, Almahdy A. Impact of the Combination of Doxorubicin, Cyclophosphamide, and Docetaxel on Ca 15-3 Biomarker Levels in Breast Cancer Patients: a Comparative Study Between Delayed and Non-Delayed Chemotherapy. Int J Appl Pharm. 2025;17(Special Issue 1):82–8. https://doi.org/10.22159/ijap.2025.v17s1.12
[2]. Fitria N, Rivaldi RS, Permatasari D. an Rinvr Scoring Evaluation of Ondansetron, Dexamethasone, and Ranitidine As Antiemetics in Breast Cancer Chemotherapy. Int J Appl Pharm. 2025;17(Special Issue 1):101–6. https://doi.org/10.22159/ijap.2025.v17s1.15
[3]. Fitria N, Rahmadani IN, Permatasari D, Handayani F. Comparative Utility of Doxorubicin , Cyclophosphamide , and Docetaxel in Breast Cancer Treatment in West Sumatera . 2024;6(2):152–60. https://doi.org/10.15408/pbsj.v6i2.40914
[4]. Fitria N, Febiana D, Akram M, Yosmar R. Aspirin-clopidogrel combination therapy for ischemic stroke patients : Clinical efficacy and. Narra J. 2024;4(2):1–10. https://doi.org/10.52225/narra.v4i2.758
[5]. Huang X, Lin D, Lin S, Luo S, Huang X, Deng Y, et al. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression. Clin Breast Cancer. 2023;23(5):508–18. https://doi.org/10.1016/j.clbc.2023.03.013
[6]. Khoirunnisa SM, Suryanegara FDA, Setiawan D, Postma MJ, de Jong LA. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis. PLoS One. 2024;19(5):1–16. https://doi.org/10.1371/journal.pone.0304483
[7]. Desriani D, Azamris A, Rustamadji P, Abna IM, Ibadurrahman I, Fuad AM, et al. Sensitive Detection of PIK3C A Exon 20 H1047R Breast Cancer Based on Low -C ost Intercalary Dye SYBR Green I Real -T ime qPCR Assay. Sains Malaysiana. 2024;53(11):3683–93.
[8]. Desriani, Azamris, Ghaissani SS, Kinanti SR, Warisman MA, Fitria N. Design and characterization of a SYBR Green I-based melting curve method for investigation of HER2I655V polymorphism in breast cancer. J Genet Eng Biotechnol. 2021;19(1):6. https://doi.org/10.1186/s43141-020-00108-9
[9]. Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, et al. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Ann Oncol Off J Eur Soc Med Oncol. 2022;32(5):1277–92. https://doi.org/10.1016/S0140-6736(23)00285-4
[10]. Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang C-Y, Ali AA, Balkrishnan R, et al. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2020;49:141–8. https://doi.org/10.1016/j.breast.2019.11.012
[11]. Leung JH, Tai Y-S, Wang S-Y, Yip Fion H-T, Tsung-Chin H, Chan AL. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer. Breast. 2022;65:91–7. https://doi.org/10.1016/j.breast.2022.07.007
[12]. NCCN. NCCN Guidelines for Patients :Invasive Breast Cancer. NCCN Foundation; 2023.
[13]. Cheng L-J, Loke L, Lim EH, Pearce F, Aziz MIA, Ng K. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):449–56. https://doi.org/10.1080/14737167.2021.1880323
[14]. Xu B, Li W, Zhang Q, Shao Z, Li Q, Wang X, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020;182(3):689–97. https://doi.org/10.1007/s10549-020-05728-w
[15]. Zhan M, Huang Z, Xu T, Xu X, Zheng H, Wu F. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04. Front public Heal. 2023;11:1049947. https://doi.org/10.3389/fpubh.2023.1049947
[16]. Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer. 2014;110(6):1472–80. https://doi.org/10.1038/bjc.2014.79
[17]. LM G, GF D, WC X, Ge H, Jiang Y, YF L. Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy. Oxid Med Cell Longev. 2022;2022:5938688. https://doi.org/10.1155/2022/5938688
[18]. Yang J, Han J, Zhang Y, Muhetaer M, Chen N, Yan X. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Front Pharmacol. 2022;13:924126. https://doi.org/10.3389/fphar.2022.924126
[19]. Nguyen AQ, Tran OTM, Nguyen PK, Nguyen HT. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam. PLoS One. 2024;19(3 March):1–17. https://doi.org/10.1371/journal.pone.0300474
[20]. Takumoto Y, Shiroiwa T, Shimozuma K, Iwata H, Takahashi M, Baba S, et al. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. Clin Drug Investig. 2022;42(3):253–62. https://doi.org/10.1007/s40261-022-01124-y
[21]. Saptaningsih AB, Nikmah US, Aryandono T, Dwiprahasto I, At Thobari J. Cost-Effectiveness Analysis of Two Chemotherapy Regiments FAC vs. Taxane for Operable Breast Cancer Patients in Indonesia. Asian Pac J Cancer Prev. 2022;23(4):1147–54. https://doi.org/10.31557/APJCP.2022.23.4.1147
[22]. Suryanegara FDA, Rokhman MR, Ekaputra E, de Jong LA, Setiawan D, de Bock GH, et al. Facing problems in radiotherapy for breast cancer patients in Yogyakarta, Indonesia: A cohort retrospective study. Cancer Med. 2023;12(7):8851–9. https://doi.org/10.1002/cam4.5634
[23]. Gautama W. Breast Cancer in Indonesia in 2022: 30 Years of Marching in Place. Indones J Cancer. 2022;16(1):1. https://doi.org/10.33371/ijoc.v16i1.920
[24]. Mahmoud Z, Elahed S, Mohamed A, Badry D. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Sohag Med J. 2018;22(1):173–9. https://doi.org/10.3892/mco.2014.419
[25]. Hasan D. Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients. Vol. 11, Journal of Circulating Biomarkers. 2022. p. 57–63. https://doi.org/10.33393/jcb.2022.2446
[26]. Renee JA. Pharmacoeconomics From Theory to Practice. Second. Renée JGA, editor. Oxon: CRC Press; 2021. 335 p.
[27]. Michael F. Drummond, Mark J. Sculpher, Karl Claxton, Greg L. Stoddart GWT, Drummond M. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. New York: Oxford University Press; 2015. 1–464 p.
[28]. Lang HC, Chen HW, Chiou TJ, Chan ALF. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016;19(10):923–7. https://doi.org/10.1080/13696998.2016.1185013